Hph1 + KALA (fusogenic peptide, non-crosslinked)
Sequence: Hph1:YARVRRRGPRR | KALA:WEAKLAKALAKALAKHLAKALAKALKACEA
| Experiment Id | EXP001243 |
|---|---|
| Paper | Multifunctional siRNA Delivery System: Polyelectrolyte Complex Micelles of Six-arm PEG Conjugate of |
| Peptide | Hph1 + KALA (fusogenic peptide, non-crosslinked) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 75 pmol (per well, transfection assay) |
| Mixing Ratio | 8 |
| Formulation Format | polyelectrolyte complex micelles (PEG-siRNA conjugate complexed with peptide) |
| Formulation Components | 6PEG-siRNA-Hph1 electrostatically complexed with KALA (non-crosslinked) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MDA-MB-435-GFP (human breast cancer cell line stably expressing GFP) |
| Animal Model | |
| Administration Route | |
| Output Type | GFP expression (% of untreated control; lower = more silencing) |
| Output Value | 61.2 ± 5.9% GFP expression at N/P 8 (10% serum) |
| Output Units | |
| Output Notes | Reported at N/P 8; transfection 4 h in 10% serum; readout at 36 h |
| Toxicity Notes | Severe cytotoxicity reported for KALA formulation at N/P 8 |
| Curation Notes |